Your browser doesn't support javascript.
loading
Cost-Sharing Requirements for the Herpes Zoster Vaccine in Adults Aged 60.
Tak, Casey R; Kim, Jaewhan; Gunning, Karen; Sherwin, Catherine M; Nickman, Nancy A; Biskupiak, Joseph E.
Afiliação
  • Tak CR; University of North Carolina at Chapel Hill, NC, USA.
  • Kim J; UNC Health Sciences at MAHEC, Asheville, NC, USA.
  • Gunning K; University of Utah, Salt Lake City, UT, USA.
  • Sherwin CM; University of Utah, Salt Lake City, UT, USA.
  • Nickman NA; Wright State University, Dayton, OH, USA.
  • Biskupiak JE; Dayton Children's Hospital, Dayton, OH, USA.
J Pharm Technol ; 35(6): 258-269, 2019 Dec.
Article em En | MEDLINE | ID: mdl-34752508
Background: Rates of zoster vaccination in US adults aged 60+ were approximately 30.6% in 2015. Out-of-pocket cost-sharing has been identified as a major barrier to vaccination for patients. To date, herpes zoster vaccine cost-sharing requirements for adults aged 60 to 64 has not been described. Objective: Compare the cost-sharing requirements for zoster vaccination in adults aged 60 to 64 and adults aged 65+. Methods: A retrospective cohort design examined pharmacy claims for zoster vaccination from the Utah All Payer Claims Database for adults aged 60+. Descriptive statistics and a 2-part cost model compared cost-sharing requirements for adults aged 60 to 64 and adults 65+. Results: Of the 30 293 zoster vaccine claims, 13 398 (45.8%) had no cost-sharing, 1716 (5.9%) had low cost-sharing (defined as $1 to less than $30), and 14 133 (48.3%) had high cost-sharing (defined as $30 or more). In the cost models, adults aged 65+ had higher odds of any cost-sharing (odds ratio = 39.86) and 29% higher cost-sharing as compared with adults aged 60 to 64. Conclusions: Adults aged 60 to 64 encounter lower cost-sharing requirements than adults aged 65+. Providers should be cognizant of this dynamic and encourage zoster vaccination prior to the age of 65.
Palavras-chave

Texto completo: 1 Temas: ECOS / Financiamentos_gastos Bases de dados: MEDLINE Tipo de estudo: Health_economic_evaluation Idioma: En Revista: J Pharm Technol Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Temas: ECOS / Financiamentos_gastos Bases de dados: MEDLINE Tipo de estudo: Health_economic_evaluation Idioma: En Revista: J Pharm Technol Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos